Researchers show amyloid beta and tau compete for microtubule binding, disrupting cellular transport. This interference may ...
An MSU-led team found promising therapeutics for two diseases that currently lack effective treatment, demonstrating how gene ...
A simulated cell in the early stages of division. Left half shows membrane (green cubes), and ribosomes (yellow/purple) interwoven through in the cell’s chromosome (red). Right side shows all the ...
This pilot run is an important validation of our cell-free platform, demonstrating that it performs reliably at scale and delivers strong results in the hands of an external partner.” — Damien ...
IBM’s architecture brings quantum and classical computing together through open software and coordinated workflows. Outlines ...
Morning Overview on MSN
New rare earth refining chemistry aims to cut reliance on China
Researchers at two U.S. Department of Energy national laboratories have developed separate chemical approaches to purifying rare earth elements, each aimed at easing key bottlenecks in the refining ...
Researchers at the Department of Energy's SLAC National Accelerator Laboratory and collaborating institutions recently built a generative AI model that can recreate molecular structures from the ...
JAXA samples reveal that asteroid Ryugu has a complete set of nucleobases, the building blocks of DNA.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage ...
Scientists have developed a network of mechanical motors that mimic the molecular machinery underpinning human muscle contraction. The University of ...
Morning Overview on MSN
New DNA base editor cuts bystander edits while keeping efficiency
Researchers have engineered a new class of adenine base editors that reduce unwanted bystander mutations by two to three times compared to the widely used ABE8e, while preserving the editing power ...
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results